Ix Biopharma Ltd. · SGX:42C
Ix Biopharma — Shareholder Meeting (October 2025)
23 slides from Ix Biopharma's shareholder meeting presentation, Oct 24, 2025
Slide 1: Corporate Presentation AGM Shareholders' Update
Corporate Presentation AGM Shareholders’ Update 24 October 2025
Slide 2: Disclaimer
Disclaimer The information in this presentation has not been independently verified. This presentation is strictly private & confidential, and is meant solely for your information only. Nothing in this presentation is or shall be considered to be an offer for the solicitation, sale or subscription o
Slide 3: Company Overview
Company Overview 1) Specialty pharmaceutical company with expertise in drug delivery systems Who we are Developed novel drug delivery platform optimised for sublingual administration of small molecules and biologics 2) Multi-drug platform delivery technology, comprising patented matrix Platform Te
Slide 4: Our Valuable Assets
Our Valuable Assets Our People 1) Leadership has extensive corporate and commercial experience 2) Backed by a team of very experience professionals including PhD specialists with backgrounds in pharmaceutical development, organic & analytical chemistry, pharmacists & medical doctors TGA licensed GMP
Slide 5: History & Background
History & Background o Listed on SGX Catalist in 2015, as a specialty pharmaceutical company with expertise in novel drug delivery and drug repurposing of approved drugs o Delivered on IPO promises, advancing development of three assets: 1) Wafermine (ketamine): Successful End-of-Phase-2 meeting wit
Slide 6: iX Biopharma Ltd
iX Biopharma Ltd Started as A Specialty Pharma, invented a novel, patented drug delivery platform, optimised for sublingual administration of small molecules and biologics Evolves into a Hybrid Model 3 Synergistic Divisions Wellness, Compounding Pharmacy (US) and Drug Development 1) Prioritise and f
Slide 7: Wellness Business
Wellness Business
Slide 8: Wellness
Wellness Nutraceuticals 1) Early success from 2 industry events held in USA o Secured a strong multi-million pipeline of B2B sales for FY2026 and FY2027 from USA, UAE, Jordan, China, Japan, Indonesia and Vietnam o Market leader: SL NAD is needle free, convenient, non-invasive alternative to IV NAD
Slide 9: Wellness Segment
Wellness Segment Wellness P&L Performa FY2025 FY2024 Changes Revenue S$'000 % Mediccal Cannabis 6,381 5,264 21% Other 274 187 47% s/total 6,655 5,451 22% Nutraceuticals 1,071 508 111% Total 7,726 5,959 30% Gross Profit 2,030 1,061 91% GP Margin 26% 18% 8% Other gain/(loss) (247) (107) 131% Expenses
Slide 10: Expansion into USA
Expansion into USA
Slide 11: US Compounding Pharmacy
US Compounding Pharmacy Compounding Pharmacies make custom-make medications for patients or hospitals when standard drugs don’t work or are not available. o 503A: Make patient-specific prescriptions; small-scale; state-regulated. o 503B: Outsourcing facilities; make drugs in bulk (including sterile
Slide 12: Transformational: Instant Monetisation, No Wait
Transformational: Instant Monetisation, No Wait US Compounding Pharmacy: A High-Growth Market Entry Our expansion into the $6.3B US compounding pharmacy market (projected to reach $10.7B by 2033, 6.1% CAGR) is a strategic accelerator for revenue, data, and market validation • First-Mover Monetizatio
Slide 13: US Expansion via Strategic Partnering
US Expansion via Strategic Partnering o Establish JV with a US Strategic Partner • Desire to expand into range of novel, superior fast dissolving solids for sublingual administration • Who has an established licensed 503B manufacturing facility • Preferably owns, operates a licensed 503A manufacturi
Slide 14: WaferiX (USA)
WaferiX (USA)
Slide 15: WaferiX for Lifestyle & Healthspan
, for Lifestyle & Healthspan o Vision: Transform WaferiX into a household name for longevity/lifespan products and services, replicating the market dominance and valuation growth of HIMS and Ro o Why HIMS/Ro? • These brands disrupted healthcare by making prescription, compounding, and wellness produ
Slide 16: WaferiX, Telehealth of Choice
, Telehealth of Choice Telehealth-enabled, mental-health, healthspan and wellness platform Longevity Hormone Mental Weight- Sexual Replace- Metric Hims (FY2024–25) Insight for WaferiX & Anti- Health Loss Health ment aging Therapy Market Cap ≈ $12 – 13B Large-cap proof of consumer-health scalability
Slide 17: Products Pipeline
Products Pipeline Pharmaceuticals, 22 products Pain, Urology, Psychiatry, Metabolic, Infectious diseases & Immunology Nutraceuticals, 7 Products Market Leader: SL NAD+
Slide 18: Out-Licensing Opportunity
Out-Licensing Opportunity Wafermine, sublingual Ketamine for Pain
Slide 19: Wafermine: Potential Strategic Collaboration
Wafermine: Potential Strategic Collaboration Invited by a leading U.S. government agency to participate in bid to supply Wafermine for acute, moderate to severe pain management o Potential collaboration to support U.S. clinical and regulatory development o In advanced discussions Potential benefits:
Slide 20: Summary
SUMMARY
Slide 21: iX Strategy: Speed to Markets, Scale & Profitability
iX Strategy: Speed 2 Markets, Scale & Profitability iX Biopharma High-Growth + Disruptive Redefining personalized medicine Wellness Compounding Drug Development 1) Nutraceuticals 1) Bypass lengthy FDA 1) iXB 401 for T2DM & o Market leader in NAD approvals Obesity products for longevity o Compounding
Slide 22: Summary
Summary 1) Wellness Business: o Revenue grew 30% from FY2024 to FY2025 to $7.7M o SL NAD for Australian Market; • Held pre-submission meeting with TGA, filing for new ingredients, approval cycle ˜12 months • Supplementary (vitamins & minerals) market size is ˜$2B in 2024, growing to $4B in 2030 at a
Slide 23: Summary: Corporate Considerations
Summary … 2 4) Corporate Considerations in the next 12 -18 months o Dual Listing at Nasdaq following establishing operating presence in USA o Potential Listing AU asset in ASX o Potential IPO WaferiX in USA